China's CARsgen Joins European Plan for Tumor Therapy
China's CARsgen Joins European Plan for Tumor Therapy
BEIJING--November 24, 2021--Researched by Industrial Info Resources (Sugar Land, Texas)--Pharmaceutical company CARsgen Therapeutics Holdings Limited (Xuhui, China) recently joined European Medicines Agency's (EMA) PRIME (Priority Medicine) plan for its CAR-T Therapy product CT041, which is used to treat solid tumors.
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- México registra inversiones por 2 mil millones de dólares en el sector farm...
- Mexico Registers US$2 Billion in Pharmaceutical Investments
- New England Sees $27 Billion in Projects Under Construction
- Pharma, Manufacturing Lead Indiana to $21.6 Billion of Projects Under Const...
- India Aims to Reduce Dependence on China for Pharma Market